Molecular Diagnosis of Breast Cancer Characteristics for Personalized Medicine

乳腺癌特征的分子诊断以实现个体化医疗

• 批准号: 17015027
• 负责人: NOGUCHI Shinzaburo
• 金额: $ 32.9万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research on Priority Areas
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2009
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17015027/
• 关键词: 乳癌; 予後; 化学療法感受性; 遺伝子発現; 細胞周期; プロファイリング; 遺伝子発現プロファイル; 細胞周期プロファイリング; 乳がん; 薬剤感受性; パクリタキセル; 悪性度; 細胞増殖; レドックス; タキサン; アンスラサイクリン; 甲状腺癌

We have been able to construct diagnostic systems for prognosis of breast cancer patients treated with adjuvant hormonal therapy alone, taking advantage of gene expression analysis and cell cycle profiling analysis. Our systems were found to be superior to the conventional clinicopathological prognostic parameters. In addition, we have been able to construct a diagnostic system for response to neoadjuvant chemotherapy consisteing of taxane followed by anthracycline in breast cancer patients.

利用基因表达分析和细胞周期谱分析，我们已经能够构建乳腺癌患者单独辅助激素治疗的预后诊断系统。我们的系统被认为是上级的传统临床病理学预后参数。此外，我们已经能够构建一个诊断系统，以反映乳腺癌患者对紫杉烷类药物联合蒽环类药物新辅助化疗的反应。

项目成果

Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy

• DOI: 10.1111/j.1524-4741.2008.00642.x
• 发表时间: 2008-11-01
• 期刊: BREAST JOURNAL
• 影响因子: 2.1
• 作者: Akazawa, Kenji;Tamaki, Yasuhiro;Noguchi, Shinzaburo
• 通讯作者: Noguchi, Shinzaburo

Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis

• DOI: 10.1007/s10549-007-9874-3
• 发表时间: 2008-12-01
• 期刊: BREAST CANCER RESEARCH AND TREATMENT
• 影响因子: 3.8
• 作者: Nakayama, Satoshi;Miyoshi, Yasuo;Noguchi, Shinzaburo
• 通讯作者: Noguchi, Shinzaburo

Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci, 2009.

干细胞标记物醛脱氢酶 1 阳性乳腺癌的特点是雌激素受体阴性、人表皮生长因子受体 2 型阳性以及 Ki67 高表达。

• 发表时间: 2009
• 期刊: Cancer Sci 100
• 作者: Morimoto K.;et al.
• 通讯作者: et al.

Ratio of cyclin-dependent kinase 1 (CDK1) activity to CDK2 activity after ex vivo paclitaxel treatment predicts response to paclitaxel in human breast cancer.

离体紫杉醇治疗后细胞周期蛋白依赖性激酶 1 (CDK1) 活性与 CDK2 活性的比率可预测人类乳腺癌对紫杉醇的反应。

• 发表时间: 2008
• 作者: Kim;S.J.;Ishihara;H.;Noguchi;S.
• 通讯作者: S.

乳癌に対するFEC100療法におけるMDM2遺伝子多型(SNP309)と骨髄抑制に関する検討

MDM2基因多态性（SNP309）与FEC100治疗乳腺癌的骨髓抑制研究

• 发表时间: 2008
• 作者: 沖代格次;他
• 通讯作者: 他